Clin Colon Rectal Surg 2024; 37(03): 172-179
DOI: 10.1055/s-0043-1770384
Review Article

Chemoprevention in Inherited Colorectal Cancer Syndromes

Ophir Gilad
1   Section of Gastroenterology, Hepatology and Nutrition, University of Chicago, Chicago, Illinois
,
Charles Muller
2   Division of Gastroenterology and Hepatology, Northwestern University, Chicago, Illinois
,
Sonia S. Kupfer
1   Section of Gastroenterology, Hepatology and Nutrition, University of Chicago, Chicago, Illinois
› Institutsangaben

Funding S.S.K received funding for this study from National Institutes of Health (NIH)/NCL. (Grant no.: R01 CA220329).
Preview

Abstract

Cancer prevention in hereditary gastrointestinal predisposition syndromes relies primarily on intensive screening (e.g., colonoscopy) or prophylactic surgery (e.g., colectomy). The use of chemopreventive agents as an adjunct to these measures has long been studied both in the general population and in hereditary cancer patients, in whom the risk of malignancy, and therefore the potential risk reduction, is considerably greater. However, to date only few compounds have been found to be effective, safe, and tolerable for widespread use. Furthermore, many of the studies involving these rare syndromes suffer from small sample sizes, heterogeneous patient cohorts, short follow-up duration, and lack of standardized endpoints, creating challenges to draw generalizable conclusion regarding efficacy. The following review summarizes the current data on various chemopreventive compounds used in Lynch syndrome and familial adenomatous polyposis in addition to several agents that are currently being investigated.



Publikationsverlauf

Artikel online veröffentlicht:
19. Juli 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA